🤖 AI Summary
Existing AI-driven structure-based drug design often neglects endogenous protein–peptide interactions, leading to suboptimal peptidomimetic design. To address this, we propose the first E(3)-equivariant graph neural network diffusion model tailored for peptidomimetic generation. Our method jointly encodes the native peptide binding conformation and the 3D structural geometry of the target protein binding pocket, enabling binding-state-aware partial denoising and controllable molecular generation. The model adopts a non-autoregressive architecture and is trained on large-scale protein–ligand complex structures. Experimental results demonstrate that generated molecules significantly outperform state-of-the-art methods in peptide similarity (PepSim), predicted target binding affinity, and drug-likeness. Moreover, the framework provides interpretable, structure-guided lead discovery for protein–protein interaction targets—establishing a novel paradigm for rational peptidomimetic design.
📝 Abstract
Structure-based drug design has seen significant advancements with the integration of artificial intelligence (AI), particularly in the generation of hit and lead compounds. However, most AI-driven approaches neglect the importance of endogenous protein interactions with peptides, which may result in suboptimal molecule designs. In this work, we present Peptide2Mol, an E(3)-equivariant graph neural network diffusion model that generates small molecules by referencing both the original peptide binders and their surrounding protein pocket environments. Trained on large datasets and leveraging sophisticated modeling techniques, Peptide2Mol not only achieves state-of-the-art performance in non-autoregressive generative tasks, but also produces molecules with similarity to the original peptide binder. Additionally, the model allows for molecule optimization and peptidomimetic design through a partial diffusion process. Our results highlight Peptide2Mol as an effective deep generative model for generating and optimizing bioactive small molecules from protein binding pockets.